USFDA completes inspection at Lupin’s Nagpur facility

14 Sep 2018 Evaluate

The United States Food and Drug Administration (USFDA) has successfully completed inspection at Lupin’s Nagpur facility, Maharashtra, India. The inspection concluded without any observation. This inspection was a product specific pre-approval inspection.

Lupin's Nagpur facility is the company's latest site and manufactures Oral Solid Dosage products. The site also houses Lupin's state of the art injectable manufacturing facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2174.20 -20.80 (-0.95%)
16-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1179.30
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2174.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×